Bio-Techne Corporation

Equities

TECH

US09073M1045

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 10:39:48 2024-07-17 EDT			5-day change	1st Jan Change
79.73 ^USD	-0.11%		+11.29%	+3.95%

07-01	Bio-Techne Corporation(NasdaqGS:TECH) dropped from Russell Midcap Growth Index	CI
07-01	Bio-Techne Corporation(NasdaqGS:TECH) dropped from Russell 3000 Growth Index	CI

Techne Corp. Announces Resignation of Gregory J. Melsen as Chief Financial Officer

January 02, 2014 at 08:00 am

Techne Corp. announced that Gregory J. Melsen will resign from his position as Chief Financial Officer, effective February 3, 2014, to pursue other opportunities. Mr. Melsen has served as Techne's Chief Financial Officer since 2004.

Latest news about Bio-Techne Corporation

Bio-Techne Corporation(NasdaqGS:TECH) dropped from Russell Midcap Growth Index	06-30	CI
Bio-Techne Corporation(NasdaqGS:TECH) dropped from Russell 3000 Growth Index	06-30	CI
Bio-Techne Corporation(NasdaqGS:TECH) dropped from Russell 1000 Value-Defensive Index	06-30	CI
Bio-Techne Corporation(NasdaqGS:TECH) dropped from Russell 1000 Growth-Defensive Index	06-30	CI
Bio-Techne Corporation(NasdaqGS:TECH) dropped from Russell 3000E Growth Index	06-30	CI
Bio-Techne Corporation(NasdaqGS:TECH) dropped from Russell 1000 Defensive Index	06-30	CI
Bio-Techne Corporation(NasdaqGS:TECH) dropped from Russell 2500 Growth Index	06-30	CI
Bio-Techne Corporation(NasdaqGS:TECH) dropped from Russell 1000 Growth Index	06-30	CI
Transcript : Bio-Techne Corporation Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 09:20 AM	06-11
Transcript : Bio-Techne Corporation Presents at Jefferies 2024 Global Healthcare Conference, Jun-06-2024 09:30 AM	06-06
Transcript : Bio-Techne Corporation Presents at The 44th Annual William Blair Growth Stock Conference, Jun-04-2024 09:20 AM	06-04
Bio-Techne Corporation to Showcase Multiple Applications of the MauriceFlex?? System at the Annual ASMS Conference	05-30	CI
Transcript : Bio-Techne Corporation Presents at 2024 Leerink Partners Healthcare Crossroads Conference, May-29-2024 08:40 AM	05-29
Bio-Techne Corporation and Regulus Therapeutics Inc. Announces Continued Technical and Clinical Collaboration	05-22	CI
Citigroup Downgrades Bio-Techne to Neutral From Buy, With $85 Price Target	05-22	MT
Bio-techne Insider Sold Shares Worth $335,377, According to a Recent SEC Filing	05-16	MT
Transcript : Bio-Techne Corporation Presents at Bank of America Health Care Conference 2024, May-14-2024 02:20 PM	05-14
Tranche Update on Bio-Techne Corporation's Equity Buyback Plan announced on February 1, 2022.	05-06	CI
Argus Adjusts Price Target on Bio-Techne to $95 From $90, Keeps Buy Rating	05-06	MT
UBS Adjusts Price Target on Bio-Techne to $90 From $80, Maintains Buy Rating	05-02	MT
Leerink Partners Adjusts Price Target on Bio-Techne to $95 From $85	05-02	MT
Scotiabank Adjusts Price Target on Bio-Techne to $83 From $80	05-02	MT
RBC Capital Adjusts Price Target on Bio-Techne to $72 From $71, Sector Perform Rating Kept	05-02	MT
Baird Adjusts Bio-Techne Price Target to $81 From $73	05-02	MT
Equity Markets Mostly Fall After Fed Leaves Rate Unchanged	05-01	MT

Chart Bio-Techne Corporation

Duration

Period

More charts

Company Profile

Bio-Techne Corporation specializes in the manufacture and marketing of products used in life science research. The group offers reagents and diagnostic tools for researchers, doctors, laboratories, pharmaceutical and biotechnology companies, etc. Net sales break down by family of products as follows: - biological and chemical reagents and analysis tools (74.3%): proteins, antibodies, molecules, culture serums, tools for cell work, tools for the study of proteins, immunoassay tools, etc.; - diagnostic and genomics products (25.7%): reagents and products used in blood analysis, nucleic acid analysis, tissue biopsy, gene analysis, cancer and genetic carrier screening, etc. Net sales are distributed geographically as follows: the United States (56.5%), the United Kingdom (4.4%), Europe/Middle East/Africa (19.4%), China (10%), Asia/Pacific (6.4%), and other (3.3%).

Sector

Biotechnology & Medical Research

Calendar

2024-08-06 - Q4 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Bio-Techne Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

79.82 USD

Average target price

84.02 USD

Spread / Average Target

+5.26%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BIO-TECHNE CORPORATION	+3.95%	12.58B
MODERNA, INC.	+23.97%	47.96B
IQVIA HOLDINGS INC.	+2.00%	42.45B
LONZA GROUP AG	+44.25%	41.47B
ALNYLAM PHARMACEUTICALS, INC.	+27.35%	31.6B
ICON PUBLIC LIMITED COMPANY	+21.64%	28.63B
CELLTRION, INC.	-6.35%	28.03B
UNITED THERAPEUTICS CORPORATION	+53.93%	14.56B
MEDPACE HOLDINGS, INC.	+46.41%	14.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.24%	11.71B

Other Biotechnology & Medical Research